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Summary The semisynthetic taxoid docetaxel was investigated in a phase 11 study in non-chemotherapy pretreated patients with metastatic
urothelial cell cancer. Thirty patients (median age 61. range 45-72) were treated with docetaxel 100 mg m-2 administered as a 1-h infusion
every 3 weeks. Of 29 evaluable patients, four achieved a complete response and five a partial response, for an overall response rate of 3100.
The median duration of response was 6 months (range 4-51+). A total of 104 cycles were administered. The median number of cycles given
was three (range 1-9). Toxic effects of docetaxel mainly consisted of neutropenia, which, however, rarely caused infectious complications
(5%). Fluid retention or neuropathy necessitated treatment cessation in two patients. We conclude that docetaxel is an effective agent in
urothelial cell cancer, and should be further tested in combination chemotherapy.
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Cisplatin and methotrexate are the txwo most commonlx used
agents in the treatment of advanced transitional cancer of the
urothelial tract (Roth. 1995. 1996). In an attempt to improxe the
results. Xarious combinations ofcisplatin and methotrexate w-ith or
wxithout other actix e agents such as x-inblastine and doxorubicin
have been studied (Sternberg et al. 1989: Roth. 1996). Although
xxith combination chemotherapy response rates have increased to
40-707. the median duration of response and survial is still less
than 1 x-ear. whereas such intensixe combination chemotherapy is
at the cost of considerable toxicity. Apart from the limited actixvitv
of these agents. intercurrent disease in this usuallv elderly patient
population may preclude treatment wxith drugs such as cisplatin
and methotrexate because of renal insufficiency. or doxorubicin
because of cardiac disease. These factors warrant the search for
new effective acgents. exen in first-line treatment.
Docetaxel belongs to the taxoids and has demonstrated activitx
in a x-ide xarietv of solid tumours. The administration schedule
determined from phase I studies is 100 mu m- in a 1-h infusion
exerv 3 wxeeks. The dose-limiting toxicitx is neutropenia. We
performed a phase II study wxith docetaxel in non-chemotherapy-
pretreated patients with metastatic urothelial cell cancer.
PATIENTS AND METHODS
Patients
Eligibility criteria required histologically prox-en transitional cell
carcinoma of the urinarx tract. measurable distant metastases or
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measurable pelvic tumour not amenable to local regional treat-
ment. performance status (WAHO scale) 0-2. serum creatinine
belowx 140 tmol 1-1. bilirubin belowx 1.25 x upper normal limit
(UNL). aspartate-aminotransferase (AS.ATT belowx 2 x UN-L. or
belowx 3 x UNL in case of proxen lixer metastases. neutrophils
above 2 x 104 1-l and platelets aboxe 100 x 041-'. Patients with
prior systemic chemotherapy. radiotherapy wxithin 4 weeks from
protocol entry. irradiated indicator lesions or brain metastases. or
xAith poor medical risk wxere excluded.
Study design
Docetaxel (Taxotere. Rhone-Poulenc Rorer. Antony Cedex.
France) x-as aiven at a dose of 100 ma m-'. even- 3 weeks.
Docetaxel as a concentrated solution in polysorbate 80 (Txxeen 80)
wxas diluted in 250 ml of dextrose 5% and administered in a 1-h
infusion. The dose was reduced by 25'k in case of neutrophils
below- 0.5 x 109 1-1 for more than 7 days. and/or complicated by
fexver (> 38.5 C rectal temperature) requingn intraxenous antibi-
otics. and/or platelets below 25 x 104 1- . Treatmentxas delayed for
1 week if neutrophils had not recoxered to aboxe 1.5 x 10 1-1. In
case of cutaneous reactions grade 2 (NCI common toxicity criteria
scale) or peripheral neuropathy grade 2. the dose was also reduced
bx 25%/. Grade 3 non-haematological toxicitx resulted in postpone-
ment of the treatment until resolution to grade 0 or 1. after which
treatment x as reinstituted. if medically appropriate. at a dose
reduction of25%. Othersxise. the patient xxas taken offstudy.
Prophylaxis for hypersensitixity reactions consisted of dexam-
ethasone 10 ma orally at 24 and 6 h before and 24 h after the
docetaxel infusion. and a single dose ofclemastine 2 ma orally 30
min before the docetaxel infusion. After reports on its beneficial
effects on the dexelopment of fluid retention and cutaneous toxi-
city. from the 24th patient onxxards in this studx. dexamethasone 8
mg, orally twice dailv wxas continued for a total of 4 day s after the
administration of docetaxel.
1342Docetaxel in urothelial cancer 1343
Table 1 Patient charactenstics
Number of patients entered
Sex (men/women)
Age median (range)
WHO performance score (0/112)
Prior treatment
Surgery
Radiotherapy
None
Sites of disease
Primary tumour
(inrduding pelvic recurrence)
Lymph node metastases only
Lung
Liver
Bone
30
2515
61 (45-72)
5/22/3
11
7
12
10
9
7
10
4
Response was assessed according to WHO criteria; a complete
response (CR) was defined as the complete disappearance of all
know n disease. determined by two obsernations not less than 4
weeks apart: partial response (PR) as at least 50%1 reduction in the
sum of the products of the two largest perpendicular diameters of
all measurable lesions. determined bv tso observations not less
than 4 weeks apart: progressive disease (PD) as an increase of at
least 25%7 in any measurable lesion or the appearance of a nes
lesion: and no change (NC) as less than 50% reduction in total
tumour volume or less than 25% increase in any measurable
lesion. Duration of partial response wvas calculated from the start
of chemotherapy to the date of first observation of progressive
disease. Duration of complete response was calculated from the
moment that the complete response was documented. Assessment
of response was performed every two cycles. In the case of a
response (CR/PR). patients continued treatment until progression.
Patients without evidence of tumour regression after two cycles
were offered cisplatin combination chemotherapy. Patients were
evaluable for response if they had completed tso cycles of
chemotherapy. unless there was rapid early progression.
Patients were esvaluable for toxicitv if they had received at least
one dose of chemotherapy. Institutional resiew board-approved
informed consent was obtained for all patients before study entry.
RESULTS
Thirty patients were entered into the study. Patient characteristics
are shown in Table 1. One patient was not evaluable for response:
the attending physician decided to switch to standard cisplatin-
based chemotherapy after one cycle of docetaxel because there
was no indication of improvement of his leg and scrotal oedema
resulting from pels ic nodal disease. Therefore. 29 patients were
evaluable for response. All 30 patients were considered evaluable
for toxicity. A total of 104 cycles were administered. The median
number ofcycles gisen was three (range 1-9).
Of the 29 evaluable patients. four patients achieved a CR: of
these one had CR in lymph node metastases lasting 4 months. the
second patient had CR in liver metastases of 13 months duration
and the third patient had a PR in lymph node and spleen metastases
that converted into a CR after 3 years of follow-up. and this
response is now lasting for 51+ months. The fourth patient had a
PR in lymph nodes and pelvic recurrence after two cycles. but died
Table 2 Toxicity
Grade (CTC)
Worst toxicity observed (per patient) 0 1 2 3 4
Leucocytes 1 1 6 11 11
Neutrophils 1 0 3 6 20
Platelets 29 1 0 0 0
Nausea/vomiting 21 6 2 1 0
Skin 20 5 5 0 0
Nall changes 21 6 3 0 0
Myalgia 19 9 2 0 0
Fatigue 14 9 6 1 0
Oedema 23 4 2 1 0
Neurosensory toxicity 15 10 4 1 0
Neuromotor toxicity 27 1 1 1 0
Diarrhoea 20 5 3 1 1
Liver enzymes (ASAT/ALAT) 22 7 1 0 0
Mucositis 17 9 4 0 0
Alopecia 0 4 26 - -
Neutropenic infectionr/sepsis - - - 3 2
Infection other 28 0 2 0 0
Hypersensitivity reactions 28 0 0 2 0
ofbleedinc from a duodenal ulcer after the third cycle. At autopsy.
there was a pathologically confirmed CR at all sites ofdisease. FiVe
patients had a partial response. Of these five patients. in three the
PRs could be confirmed at follow-up CT-scans. one patient had a
PR after two cycles. but died ofbowel perforation (due to divertic-
ulitis coli. without concurrent neutropenia) following the third
cycle. and one patient had a more than 50%7 regression of liver
metastases after the first cycle. but Aas subsequently lost to follow-
up. Sites of response were ly%mph node metastases (three). liver
metastases (two). pelvic recurrence (one). The duration of
confirmed partial responses was 4. 5 and 9 months. Thus. there
were nine (3197) responses out of 29 evaluable patients. Two
patients briefly had more than 50% regression observed after two
cycles. but had progression after four cycles and. thus. only quali-
fied for no changye. Another seven patients had no change after two
(five patients) or four (two patients) cycles. and 11 patients had PD.
Twelve patients were eventually crossed over to cisplatin-based
chemotherapy. of whom four achieved PR. three had NC and five
had PD. None of these four partial responders had initially
responded to docetaxel. Conversely. of the three patients who had
NC during docetaxel treatment and decided to cross over to
cisplatin-based chemotherapy. none responded. Of the 13 patients
who did not cross ouer to cisplatin-based chemotherapy. eight had
refused a second line regimen. and five were inelioible because of
clinical deterioration. performance status (two). or renal function
impairment (three).
Toxicity
The most frequent toxicities are listed in Table 2. The most
frequent toxicity was neutropenia. which. however. w-as rapidly
reversible: recoverv from nadir was usually observed within a few
davs and never lasted more than 7 days. There were five episodes
of neutropenic fever in a total of 104 cycles (5%7). 95 of w-hich
were aiven at 100%c dose. and nine at 75% dose. Other frequent
toxicities included myalgia and fatigue which were usually rrades
1 and 2 startinc on davs 3-5 after treatment and aradually
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Table 3 New agents in urothelial cell cancer
Agent Number of Prior Overall Reference
patients chemotherapy response
(%)
Piritrexim 29 Untreated 38 de Wit. 1993
Gemcitabine 15 14 Untreated 27 Pollera et al. 1994
37 Untreated 24 Moore et al. 1997
39 Untreated 28 Stadler et al. 1997
27 Pretreated 26 de Lena et al. 1996
Paclitaxel 26 Untreated 42 Roth et al. 1994
14 Pretreated 7 Papamichael et al. 1997
Docetaxel 30 Untreated 31 Present study
20 Pretreated 20 McCaffrey et al. 1995
resolvxing oxer the next w-eek. In addition. fluid retention >-as a
cumulatix e side-effect which necessitated treatment cessation in
txxo patients. Once treatment >-as stopped. the fluid retention
slowxlv diminished and disappeared. wxhich in some cases took
more than a vear. After the standard use of dexamethasone for 4
daxvs after docetaxel (from the 24th patient onw-ards . both the inci-
dence and the sexenrtv offluid retention and onvcholvsis appeared
to be obserxed less frequentlx: one out ofsexen patients dexeloped
grade 1 oedema and one patient had grade 1 onxycholx sis.
Neuropathy. mainlx sensorx. >-as also a cumulatixe side-effect that
caused treatment interruption in tw-o patients: one patient had
grade 2 sensorx neuropathx after sexen cycles. that slowlx recox-
ered upon cessation of treatment. the second patient had grade 3
combined sensorx and motor neuropathy and subsequent disabilitv
after fixe cycles. This patient had a CR of liver metastases for 1.
months. is currentlx alixe with disease after more than 18 months.
and during this time period his neuropathv has improxved. but not
completely disappeared. Two patients had hypersensitixitx reac-
tions grade 3. after the start ofthe second cvcle. that rapidix disap-
peared upon interruption of the docetaxel infusion. one additional
dose of dexamethasone 10 mg ix. plus clemastine 2 mg iLx.. and
that did not recur w-hen docetaxel administration w-as resumed.
DISCUSSION
The current standard first-line chemotherapy in metastatic bladder
cancer is the MVAC regimen (Steinberg et al. 1988: Roth. 1996).
comprising methotrexate. xinblastine. doxorubicin and cisplatin.
and designed on the basis of the singzle-agent actixvit- of these
agents reported in phase II trials (Yagoda. 1987). The agents in this
regimen that are considered most active are cisplatin with an
oxerall response rate of 35Cc. rangze 26-65%-. in a total of nine
phase II trials. and methotrexate with an oxerall response rate of
30%c in pooled phase II data (Yagoda. 1987: Roth. 1995: Roth.
1996). How-exer. in more recent studies. response rates with
conxentional singale agents haxe been less encouraging: in fixe
phase III trials that contained single-agent cisplatin as one treat-
ment arm. the oxverall response rate has decreased to 17c% (range
9-31 Cc ). These differences in response rates may represent differ-
ences in patient selection. as wxell as the use of strict response
criteria and independent response rexiew. Of note. in the largest
and most recent trial. cisplatin had onlx a 12%- response rate. 3%
complete response rate and a median sun rixal of 8 months
(Loehrer et al. 1992: Saxman et al. 1997).
Nexvertheless. these agents hax-e become integral components of
combination chemotherapy regimens. and these regyimens hax-e
appeared to significantly increase the response rates. In the initial
series of 121 patients treated at Memorial Sloan Kettering Cancer
Center wxith the four-drugy recaimen of M\AC. the response rate
xxas 72%;. wxith 36%- CRs and a median survixal of 13 months
(Stemnberg et al. 1989).
Hoxxexer. similar to the studies wxith single agents. subsequent
trials of MIVAC at other institutions hax-e showxn lower response
rates ranging from 40%;c to 57%. When all data on MVxAC are tak-en
together. in a total of509 patients the oxerall response rate is 52%.
,x-ith 25c CRs. Therefore. exen in the optimal patient categorx
agaed less than 65 vears and haxing a good WHO performance
status and organ function. the combination chemotherapy regimen
of MVAC is palliatixve treatment in the xast majority of patients.
and there is clearlv a need for nexx effectixe agents in this disease.
In addition. urothelial cell cancer predominantly occurs in the
elderly frail patient population wxith a frequently suboptimal renal
function. hence toxic regyimens and particularlv nephrotoxic agents
such as cisplatin and methotrexate cannot be administered to all
patients.
During the past 5 xyears. sexeral newx agents haxe demonstrated
considerable actixvitv in urothelial cell cancer (Table 31. Piritrexim.
a lipid soluble dihxdrofolate reductase inhibitor. in a prolonged.
lowx-dose oral schedule in 29 prexviously untreated urothelial cell
cancer patients resulted in ten PRs and one CR for an ox-erall
response rate of 38%-. wxith a median duration of response of 5
months (De Wit et al. 1993). Unfortunatelv. this drug xxas wxith-
drawxn from further dexelopment for a number ofxvears.
The nox-el pynrimidine antimetabolite 2emcitabine has been
inxestigated for its single-agent actixity in four trials. including a
total of 83 prex iously untreated patients and 27 pretreated patients
showxing oxerall response rates of 29%- and 26%- respectixely
(Pollera et al. 1994: De Lena et al. 1996: 'Moore et al. 1997:
Stadler et al. 1997).
Preclinical studies hax-e showxn the antiproliferatixe actixvit- of
taxoids against human urothelial cancer cell lines and superioritx of
these agents compared wxith classic microtubular inhibitors Niell et
al. 1993: DeHaxen et al. 1995). In a phase II trial in 26 prexiously
untreated patients. using a dose-intensixve schedule of paclitaxel
(Taxol) at 250mc m-x with _ranubcvte colonv-stimulatin2 factor
(G-CSF) support. an oxerall response rate of 42%- x-as reported.
including an impressixe 27% CR rate. The median duration of
response with paclitaxel at this dose xxas 11 months. In another
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phase II trial ofpaclitaxel given at a more conventional dose of200
ma m-' in chemotherapy pretreated patients. only 1 out of 14
patients (79%) achieved a partial response (Papamichael et al. 1997).
With the use ofthe semisynthetic taxoid docetaxel. in a phase II
study in cisplatin-based chemotherapy pretreated patients. 4 out of
20 patients (20%7c) achieved a PR (McCaffrey et al. 1995).
The present study is the first to report on the activity ofdocetaxel
in previously untreated patients with urothelial cell cancer. In this
unselected series of patients. several of whom had significant
hepatic. pulmonary. and/or osseous metastases. who often do not
benefit from chemotherapy. we obtained four complete (14%7) and
five partial responses (171%7). for an overall response rate of 31%7.
The median duration ofresponse was 6 months. Docetaxel is. thus.
an active agent in the treatment of urothelial cell cancer. The stan-
dard use of prolonged administration of dexamethasone from
halfway through the study reduced fluid retention and skin toxicitv
to infrequent and manageable side-effects. Mild or moderate
sensorv neuropathy was frequently observed, but gradually devel-
oped and. as has been reported in the recent literature, severe and/or
disabling neurotoxicity rarely occurred before a cumulative dose of
docetaxel of600 mg m-' (Hilkens et al. 1996).
We have recently shown in a phase I study that the combination
ofdocetaxel and cisplatin is feasible. at their common single-aaent
doses (Pronk et al. 1997). Likewise, several phase I and early
phase II studies in various tumour types have been carried out with
the combination ofpaclitaxel and cisplatin. with paclitaxel and the
platinum analogue carboplatin. and with gemcitabine in -arious
combinations. Given the overlapping 95% confidence limits of
response rates. it is difficult to determine eventual superiority of
one of the new agents. Both the incorporation of new agents in an
MVAC type of regimen or vanrous combinations of these new
agents with or without cisplatin deserve further testing in phase II
and eventually phase III studies in urothelial cell cancer. Of par-
ticular interest in this respect would appear the triplet combination
of a taxoid. gemcitabine and cisplatin in the optimal patient cate-
,uorv. and doublet combinations in the elderly patient population.
We conclude that docetaxel is an activeagent in the treatment of
metastatic urothelial cell cancer. Docetaxel is one of several new
agents that should be further tested in combination chemotherapy
regimens in this disease.
REFERENCES
DeHaven JI. Travnelis CT. Riggs D. Fenton J and Lamm DL 1995 Taxol v-ith or
without cisplatin reduces the growth oftransitional cell carcinoma and prostatic
carcinoma cell lines in vitro. Proc .Am .Assoc Cancer Res 36: 297
De Lena NI. Gnrdelli C. Lorusso V. Amadori D. Antimi MI. Luponrni G. Pollera C and
Olisa C 1996) GemTcitabine actis-it\ (objecuti-e responses and ssmptom
improvement in resistant stage IN bladder cancer. Proc Am Sck Clin Oncol 15:
246
De AWit R. Kase SB. Roberts JT. Stoter G. Scott J and Vers eij J 1993 Oral
pintrexim. an effective treatment for metastatic urothelial cancer. BrJ Cancer
67: 388-390
Hilkens PHE. Verweij J. Stoter G. Vecht ChJ. san Putten AWL and san den Bent NU
(19961 Peripheral neurotoxicit induced by docetaxel. Neurologv 46: 104-108
Loehrer PJ. Einhorn LH. Elson PJ. Craw%ford DE. Kuebler P. Tannock [. Raghasan
D. Stuart-Hamrs R Sarosd% MIF. Lose BA. Blumenstein B and Trump D
(19921 A randomized comparison of cisplatin alone or in combination s-ith
rnethotrexate. sinblastine. and doxorubicin in patients with metastatic
urothelial carcinoma: a cooperatise group stud\. J Clin Oncol 10: 1066-1073
McCaffrev J. Hilton S. Bajorin D. Mazumdar NI. Amsterdam A. Kim B and S-her H
(1995 )Doceta.xel in patients w-ith adsanced transitional cell cancer -ho failed
cisplatin-based chemotherapx. Prnc Am Soc Clin Oncol 14: 2'33
Moore NIJ. Tannock IF. Ernst DS. Huan S and NMurrav N (19971 Gerncitabmne: a
promising new agent in the treatment ofadsanced urothelial cancer. J Clin
Oncol 15: 341-3145
Niell HB. Rangel C. MIiller A and Cox C (19931 The actisvits of antimicrotubular
agents in humnan bladder tumor cell lines. Proc .Am Assoc Cancer Res 34: 202
Papamichael D. Callagher CJ. Oliser RTD. Johnson PW and Waxman J1(9971
Phase II study ofpaclitaxel in pretreated patients swith locallv
adsanced/metastatic cancer ofthe bladder and ureter. BrJ Cancer 75: 606-607
Pollera CF. Ceribelli A. Crecco MI and Calabresi F (19941 Weeklv 2emcitabine in
adsanced bladder cancer. a preliminars report from a phase I study. Ann Oncol
5: 182-184
Pronk LC. S-hellens JIHL. Planting ASTh. \an den Bent NU. Hilkens PHE. van der
Bum MEL de Boer-Dennert MI. MIa J. Blanc C. Harteseld MI. Bruno R. Stoter
G and Versweij 1 19971 Phase I and pharmacolo ic study ofdocetaxel and
cisplatin in patients with advanced solid tumors. J Clin Oncol 15: 1071-1079
Roth BJ (1995) Palliative chemotherap! in ads anced bladder cancer. Semin Oncol
22: 10-15
Roth BJ (1996) Chemotherapy for adsvanced bladder cancer. Semin Oncol 23:
633-644
Roth BJ. Dreicer R. Einhorn LH. Neubere D. Johnson DH. Smith JL. Hudes GR.
Schultz SMI and Loehrer PJ 119941 Significant activits ofpaclita.xel in
adsvanced transitional-cell carcinoma ofthe urothelium: a phase II trial ofthe
Eastem Cooperatise Oncologs Group. J Clin Oncol 12: 2264-2270
Saxman SB. Propert Kl. Einhom LH. Craw%ford ED. Tannock I. Raghasan D.
Loehrer PJ and Trump D (19971 Long-term follow-up of a phase III intereroup
study ofcisplatin alone or in combination swith methotrexate. vinblastine. and
doxorubicin in patients w-ith metastatic urothelial carcinoma: acooperatis e
group study. J Clin Oncol 15: 2564-2569
Stadler A-M. Kuzel T. Roth B. Rarhaven D and Dorr FA 119971 Phase II stud\ of
single-agent emncitabine in previously untreated patients with metastatic
urothekhal cancer. J Clin Oncol 15: 3394-3398
Sternberg CN. Yagoda A. Scher HI. Watson RC. Geller N. Herr HW. Morse NU.
Sogani PC. Vaughan ED. Bander N. Weiselberg L. Rosado K. Smart T. Lin SY:
Penenbere D. Fair A-R and AWitmore AT (19891 Mlethotrexate. vinblastine.
doxorubicin. and cisplatin for ads anced transitional cell carcinoma of the
urothelium. Cancer 64: 2448-2458
Yagoda A (19871 Chemotherapy of urothelial tract tumors. Cancer 60: 574-585
© Cancer Research Campaign 1998 British Joumal ofCancer (1998) 78(10), 1342-1345